Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05518773 · ClinicalTrials.gov registry record

Mechanisms and Treatment of Exercise Intolerance and Persistent Fatigue in Spinal Muscular Atrophy

A clinical trial of Spinal Muscular Atrophy, sponsored by Columbia University.

Completed
Registry status
34
Enrollment target
1
Study location

NCT05518773 is a study of Spinal Muscular Atrophy that has completed, run by Columbia University. The registered enrollment target is 34 participants, below the 108-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05518773, a study of Spinal Muscular Atrophy, has completed, sponsored by Columbia University.

COMPLETED
Registry status
34 participants
Enrollment target
1
Study location

Study Summary

This study will focus on the pathophysiological underpinnings of reduced exercise capacity and fatigue in ambulatory patients with spinal muscular atrophy (SMA). There has been laboratory evidence to suggest that the molecular mechanisms underlying mitochondrial biogenesis may be vulnerable to survival motor neuron (SMN) protein deficiency. This is an observational, single visit study including 34 ambulatory SMA patients treated with SMN repletion therapies (risdiplam or nusinersen) for at least 6 months at enrollment.

Conditions Studied

Interventions

  • OTHER Observational

Study Locations (1)

New York

  • Columbia University Irving Medical Center - New York

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2022-12-15
Est. Completion 2025-11-14

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT05518773

The ClinicalTrials.gov registry entry for NCT05518773 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (69% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.

NCT05518773 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05518773 about?

NCT05518773 is a clinical study titled "Mechanisms and Treatment of Exercise Intolerance and Persistent Fatigue in Spinal Muscular Atrophy". This study will focus on the pathophysiological underpinnings of reduced exercise capacity and fatigue in ambulatory patients with spinal muscular atrophy (SMA). There has been laboratory evidence to suggest that the molecular mechanisms underlying mitochondrial biogenesis may be vulnerable to survi...

What is the current status of trial NCT05518773?

This trial is currently completed. The enrollment target is 34 participants. The study started on 2022-12-15. Estimated completion is 2025-11-14.

What conditions does trial NCT05518773 study?

This clinical trial studies the following conditions: Spinal Muscular Atrophy.

What interventions are being tested in trial NCT05518773?

The interventions under investigation include: Observational (OTHER).

Who is sponsoring clinical trial NCT05518773?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05518773 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Muscular Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.